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ABSTRACT
Diclofenac a phenylacetic acid derivative has long been used 
as an anti-inflammatory and analgesic drug to treat certain 
conditions however its sustained release formulation with 
immediate release loading dose is desirable. The rationale 
of the current work was to develop and evaluate bilayer 
tablets with diclofenac potassium as orodispersible layer and 
diclofenac sodium as sustained release core. The diclofenac 
sodium core was prepared by wet granulation method while the 
orodispersible outer layer was prepared by direct compression 
method using super disintegrant sodium starch glycolate. The 
powder blends were then evaluated for both pre- compressional 
and post compressional properties. The physical parameters 
of both powders and tablets were in accordance with the 
compendial standards. The orodispersible portion disintegrated 
in less than 30sec releasing diclofenac potassium as the loading 
dose while the core was able to sustain the release of diclofenac 
sodium up to 10hrs in simulated intestinal fluid (pH 6.8). The 
kinetic data revealed that the release pattern was best fitted into 
Korsmeyer-Peppas model with non-fickian release. The outer 
orodispersible layer of diclofenac potassium and sustained 
release inner core of diclofenac sodium in a single tablet was 
successfully formulated while sodium starch glycolate showed 
to have good super disintegrant properties.
Keywords: Orodispersible, Sustained release, Diclofenac, Direct 
Compression, Bilayer tablet.
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Formulation and evaluation of a bilayer tablet comprising of diclofenac 
potassium as orodispersible layer and diclofenac sodium as sustained 
release core
INTRODUCTION
The increased costs in the discovery of new drug molecules 
has turned the focus of researchers to formulate dosage forms 
with altered release mechanisms (1). Oral route is the most 
ancient and well acknowledged route of drug administration 
and has been used for both conventional and novel drug 
delivery systems due to its cost effectiveness, ease in drug 
administration and improved patient compliance. In the 
past few years modified release dosage forms have limited 
the use of conventional dosage forms to a larger extent due 
to reduction in dosage frequency and improved patient 
compliance (2). The oral route on the other hand has some 
limitations like first pass metabolism and degradation of 
the drug in the presence of gastrointestinal enzymes which 
confines the administration of certain classes of drugs like 
proteins and peptides through this route. This route is also 
non-suitable in conditions when quick onset of action is 
required (3). To overcome this problem, the other absorptive 
mucosal barriers that are involved in the absorption like 
Abbas et al.
A bilayer tablet comprising of diclofenac potassium and diclofenac sodium Marmara Pharm J 21/3: 707-716, 2017708
ocular, nasal, oral, vaginal and rectal are being considered as 
potential sites for drug absorption.
Orodispersible dosage forms are an emerging class of medicines 
and a new drug delivery system. When these dosage forms are 
placed on tongue the saliva disintegrates and dissolves them in 
less than a minute without the need of chewing/water, liberating 
the drug free for oral absorption (4). Rapid disintegration 
followed by rapid dissolution and absorption results in quick 
onset of action (5). Opposing to conventional immediate 
release dosage forms sustained release matrix tablets assure 
better patient compliance through reduction in the total dose, 
which is of great importance when patients are supposed to go 
through chronic treatment regimen (6). This makes sustained 
release dosage forms a better alternative especially for drugs 
which have peak plasma levels linked with adverse effects. 
Sustained release matrix tablets are formulated mainly by wet 
granulation, direct compression or solid dispersion method 
using polymers like poly methyl methacrylate (PMMA), poly 
glycolic acid (PGA), hydroxypropyl methyl cellulose (HPMC), 
ethyl cellulose (EC) etc. The retardant materials may be of 
hydrophilic, hydrophobic, mineral or biodegradable types and 
aid in controlling the release of drug from the matrix core.
The simplest and common method of prolonging the drug 
release from an oral dosage form is to incorporate the drug 
in an inert polymer matrix. In solvent activated drug delivery 
system the interaction between polymer and water which 
results in plasticization, erosion, swelling or degradation of 
polymer is responsible for achieving sustained release. In gel-
forming hydrophilic matrix systems the drug is dispersed in 
a swellable hydrophilic polymer. The hydrophilic polymer 
starts swelling and becomes plasticized due to chain 
relaxation and resultant volume expansion upon contact 
with the aqueous gastrointestinal fluids. The release of 
dissolved drug mainly occurs through diffusion within the 
swollen gel layer. An attempt has been made recently to 
formulate domperidone tablets with both orodispersible 
and sustained release technology holding the convenience 
of administration, quick clinical response and benefits of 
controlled release product at the same time. The developed 
technology provides an easy approach and seeks exploitation 
for commercial use in future (7). Diclofenac is the most 
commonly prescribed non-steroidal anti-inflammatory drug 
(NSAID), that has shown to be useful in the treatment of a 
variety of painful conditions (8).
The rapid systemic clearance of diclofenac makes it a suitable 
candidate to be formulated as SR dosage form to prolong 
drug action, and improve patient compliance and till date few 
formulations are available as market products (9). Diclofenac 
almost absorbs completely after oral administration however 
it is taken up by the hepatic portal system before reaching 
the systemic circulation and about 50% of the drug is lost. 
Polymers play an important role in formulation and are 
long been used in targeted drug delivery systems because 
of their unique properties. The drug is homogeneously 
dispersed in hydrophilic or hydrophobic polymer matrix 
(10). Hydrophilic polymers hydrate upon contact with 
water and converts into a gel like structure through which 
the drug diffuses. To produce action for longer duration 
it is important that the dosage form should remain intact, 
stay longer in the stomach or upper part of intestine and 
the drug is released at a controlled rate (11). Drug release 
occurs from hydrophilic matrices as a result of multifaceted 
interaction between the mechanisms of absorption, swelling, 
dissolution, diffusion and erosion (12). HPMC is a semi-
synthetic derivative of cellulose and is the first choice to be 
used for years in hydrophilic matrix systems as swellable 
hydrophilic controlled release polymer (13). Figure 1 shows 
the chemical structure of HPMC.
Figure 1. Structure of HPMC
The use of sodium starch glycolate as disintegrant in oral 
pharmaceuticals has been since long in capsules (14) 
and tablet formulations (15). It is a commonly employed 
polymer in tablets manufactured either through direct-
compression or wet-granulation processes (16). It is 
usually employed in the concentration between 2% and 
8% during formulation. Disintegration occurs as a result of 
rapid uptake of water followed by immediate swelling. The 
current work is focused on developing of a bilayer tablet 
containing diclofenac potassium in the outer orodispersible 
shell and diclofenac sodium as sustained release in the 
inner core. The objective of the study is to improve 
therapeutic efficacy by giving quick relief from pain with 
reduced toxicity. Different drug polymer ratios will be used 
by employing primogel® as super disintegrant and HPMC as 
release modifying polymer.
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MTERIALS AND METHODS
CHEMICALS
Diclofenac sodium and Diclofenac potassium were 
received as gift samples from Saffron pharma Faisalabad, 
Pakistan. Lactose, HPMC K-15 and Magnesium stearate 
were purchased from DMV-Fonterra Germany, Zhongbao 
chemicals China and Peter Greven Asia Malysia respectively. 
Primogel® (sodium starch glycolate) and Avicel PH-200 
(Microcrystalline cellulose) were purchased from Mingtai 
chemical, Taiwan. All the chemicals and solvents used were 
of analytical grade
METHOD OF PREPARATION
Preparation of Matrix Tablet
Diclofenac sodium, lactose and sufficient amount of HPMC 
K-15 were all mixed together in horizontal mixer after 
passing through mesh of sieve size 60 and slowly added 
purified water until a slightly wet mass is obtained. The damp 
mass was placed in stainless steel trays inside hot air oven 
and dried at a temperature of 600C. After drying the dried 
material was passed through mesh of sieve size 30 to obtain 
granular mass. Add magnesium stearate to the remaining 
amount of HPMC K-15 and pass through mesh of sieve 
size 60 to obtain uniform mixing (17). The dried granules 
are then added with the lubricant mixture and mixed for 
5min. The bulk was then compressed into tablets using 
ZPW rotary press machine (China) (18). Table 1 indicates 
the composition of all sustained release formulations of the 
model drug.
Preparation of Orodispersible layer
Specified quantities of diclofenac potassium, avicel and 
primogel were sifted through mesh of sieve size 60 and mixed 
thoroughly for 15min to obtain a uniform blend. The contents 
were mixed further for 5min after the addition of magnesium 
stearate previously sifted through mesh of sieve size 60. After 
lubrication (with talcum) the final tablets were compressed 
in such a way that the first and third hopper contain the 
powder blend while the second hopper contain diclofenac 
sodium sustained release tablets as previously described by 
Gohel et al; 2010 (19). Table 2 indicates the composition of 
orodispersible formulations of the model drug.
CHARACTERIZATION
Pre-compression properties of powder blend
The granules were evaluated for pre-compressional properties 
like bulk density, tapped density, angle of repose, carr’s index 
and Hausner ratio (20).
Post-compression properties of tablets
The prepared tablets were characterized after their final 
compression for weight variation, tensile strength, thickness, 
friability and assay of active drug contents (20).
Table 1. Composition of various formulations of sustained release core of diclofenac sodium
Formulation Diclofenac Sodium(mg)
HPMC K-15
(mg)
Lactose
(mg)
Magnesium stearate
(mg)
T-01 50.0 13.5 38.5 3.0
T-02 50.0 11.5 38.5 5.0
T-03 50.0 16.0 38.0 1.0
T-04 50.0 17.5 36.5 1.0
Table 2. Composition of various formulations of orodispersible layer of diclofenac potassium
Formulation Diclofenac potassium(mg)
Avicel
(mg)
Primogel®
(mg)
Mag. stearate
(mg) Talcum (mg)
T-01 50.0 296.5 26.5 8.3 3.3
T-02 50.0 308.0 20.0 2.3 4.3
T-03 50.0 301.5 28.5 2.3 2.3
T-04 50.0 301.5 26.5 3.3 3.3
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In-Vitro Drug Release
In-vitro drug release studies were performed using USP 
type-II apparatus. The dissolution study for orodispersible 
layer was carried out in phosphate buffer pH 6.8 for 2 min 
using 900ml of phosphate buffer placed in each vessel of 
the apparatus and maintained at a temp of 37 ± 0.5oC. 
Each vessel was added single tablet and the apparatus is 
allowed to run at a speed of 50 rpm. An aliquot of 3ml was 
withdrawn at specific time intervals and analyzed by UV-
visible spectrophotometer. Similarly, the dissolution study 
for diclofenac sodium sustained release tablets was carried 
out initially for 2hrs in 0.1 N HCl and then for eight hours 
in phosphate buffer pH 6.8 under the same conditions as 
above. 5ml aliquot was withdrawn from the dissolution 
medium at specific time intervals and analyzed by UV-visible 
spectrophotometer for diclofenac contents at a wavelength 
of 276nm. After every withdrawal, 5ml of freshly prepared 
pre-warmed dissolution medium was added to the vessel in 
dissolution apparatus to keep its volume constant. Finally, 
the amount of percent drug release was determined for all 
formulations.
Drug Release Kinetics
Various kinetic models were applied to evaluate the possible 
drug release mechanism. The kinetic models and their 
equations are as follows;
Zero order rate equation Q = kt (21)
First order rate equation In (100 - Q) = In 100 – Kt (22)
Higuchi model equation Q = K3√ t (23)
Hixon – Crowell model A01/3 – At1/3 = kst (24)
Korsmeyer Peppas Equation Mt / Mα = Ktn (25)
RESULTS
Pre-compression properties of granules and powders
During evaluation of the flow properties the angle of 
repose for all formulations of diclofenac sodium as well as 
diclofenac potassium is below 30o as presented in Tables 3 
and 4 respectively which shows that granules and powders 
have good flow behavior. The Carr’s index values were found 
to be less than 20% and 25% in case of diclofenac sodium 
and diclofenac potassium respectively. These results were 
supported by Hausner’s ratio which in both cases is less 
than 1.4. The same behavior was also reported previously by 
Murtaza et al; 2010 (26).
Post-Compressional properties of tablets
The results of the post compressional studies found for 
weight variation 105 ± 5% for diclofenac sodium sustained 
release core and 500 ± 5% for final tablet, thickness in the 
range of 3.20mm–3.30mm in case of diclofenac sodium 
core and 5.60mm-5.71mm in case of final tablet, hardness 
Table 3. Evaluation of granules of diclofenac sodium sustained release core
Diclofenac sodium sustained release
Formulation code Angle of Repose Bulk density (g/ml) Tapped density (g/ml) Carr’s Index(%) Hausner ratio
T-01 29.93 ± 0.18 0.713 ± 0.02 0.850 ± 0.001 18.16 ± 0.02 1.19 ± 0.02
T-02 29.65 ± 0.09 0.780 ± 0.05 0.833 ± 0.003 16.13 ± 0.04 1.15 ± 0.06
T-03 29.30 ± 0.18 0.731 ± 0.01 0.879 ± 0.002 16.20 ± 0.03 1.18 ± 0.03
T-04 29.56 ± 0.18 0.758 ± 0.04 0.893 ± 0.006 15.15 ± 0.06 1.19 ± 0.01
All data are reported as mean ± standard deviation, n= 3 per experiment
Table 4. Evaluation of granules of diclofenac potassium outer orodispersible layer
Diclofenac potassium orodispersible outer layer
Formulation code Angle of Repose Bulk density (g/ml) Tapped density (g/ml) Carr’s Index(%) Hausner ratio
T-01 29.31 ± 0.11 0.399 ± 0.01 0.530 ± 0.003 25.38 ± 0.02 1.336 ± 0.02
T-02 28.63 ± 0.09 0.390 ± 0.01 0.529 ± 0.005 25.11 ± 0.04 1.335 ± 0.06
T-03 26.38 ± 0.12 0.383 ± 0.03 0.523 ± 0.001 26.30 ± 0.01 1.338 ± 0.03
T-04 25.56 ± 0.18 0.403 ± 0.04 0.538 ± 0.006 24.99 ± 0.06 1.333 ± 0.01
All data are reported as mean ± standard deviation, n= 3 per experiment
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in the range of 2.903Kg/cm3-3.703Kg/cm3 in both cases, 
friability less than 1% in both case and disintegration of 
the orodispersible coat takes place within 21-30sec for all 
formulations developed. The cumulative results shown in 
Tables 5 and 6 indicates that all formulations are within the 
specified limits according to USP (27). All the results were 
produced in triplicate.
Pharmaceutical Assay
The percentage of active drug in each tablet was measured 
by performing the assay on tablets from each formulation. 
Tables 5 and 6 shows the respective percent drug contents of 
both diclofenac sodium and diclofenac potassium which fall 
in the official limits (27).
In-vitro Dissolution Profile
Dissolution data presented in Table 7 shows the complete 
drug release profile with respect to time which revealed 
that all the formulations impeded the drug release from 
matrices for initial 02hrs but as the medium was changed 
to phosphate buffer the drug release initiated and 
increases with time as previously observed by Kramar, 
Turk and Vrečer, 2003 (28). The percent drug release with 
respect to time is mentioned in table (7). A slight change 
Table 5. Physical parameters of diclofenac sodium sustained release tablets
Diclofenac sodium sustained release
Formulation code Average weight (mg) Thickness (mm) Hardness (Kg) Friability (%) Assay (%)
T-01 105.5 3.23 3.02 0.16 99.23
T-02 104.0 3.22 3.00 0.17 98.03
T-03 104.5 3.20 3.20 0.13 99.91
T-04 106.0 3.30 3.50 0.15 101.33
All data are reported as mean ± standard deviation, n= 3 per experiment
Table 6. Physical parameters for diclofenac potassium orodispersible tablet incorporating diclofenac sodium sustained release 
tablet.
Formulation Code Average Weight (mg) Thickness (mm) Hardness (Kg) Friability (%)
Disintegration 
time (sec.) Assay (%)
T-01 499.0 5.68 3.70 0.65 25.0 90.33
T-02 502.2 5.71 3.30 0.73 30.0 91.48
T-03 501.0 5.70 3.70 0.71 21.0 92.01
T-04 503.8 5.60 2.90 0.60 23.0 97.45
All data are reported as mean ± standard deviation, n= 3 per experiment
Table 7. Dissolution profile of diclofenac sodium sustained release
Formulation
Drug Release %
0 hr 1st hr 2nd hr 3rd hr 4th hr 6th hr 10th hr
T-1 0% 0% 0% 15.92% 30.81% 50.12% 65.77%
T-2 0% 0% 0% 11.83% 25.70% 56.44% 62.13%
T-3 0% 0% 0% 18.01% 40.25% 61.36% 70.11%
T-4 0% 0% 0% 21.96% 39.84% 63.36% 76.94%
All data are reported as mean ± standard deviation, n= 3 per experiment
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in HPMC concentration among formulations T-01 & T-04 
showed significant differences in drug release behavior 
from hydrophilic matrices. It was the concentration of 
HPMC that was principally responsible for controlling 
drug release from the swollen matrices which means that 
release of diclofenac sodium was found to be dependent 
on the concentration of the polymer used.
The cumulative dissolution profiles of all formulations 
describes a correlation between % drug release and time as 
shown in figure (2).
Drug Release kinetics:
Dissolution data obtained was fitted in to different kinetic 
models. The values of correlation coefficient for equations 
are presented in Table 8.
Figures 3-6 indicates the drug release profile of all 
formulations following Korsmeyer-Peppas Model.
Table 8. Values of correlation coefficient fitted in to various kinetic models
Formulation Zero order Model First order Model HiguchiModel Hixson-Crowell Model Korsmeyer Peppas Model
ko R2 K1 R2 kH R2 kHC R2 kP N R2
T-01 7.567 0.932 0.119 0.959 34.23 0.954 0.461 0.700 1.940 0.864 0.993
T-02 7.342 0.906 0.121 0.939 33.39 0.927 0.461 0.714 2.029 0.881 0.994
T-03 8.347 0.882 0.140 0.932 37.82 0.915 0.474 0.668 2.108 0.871 0.991
T-04 8.989 0.909 0.165 0.953 40.62 0.939 0.485 0.672 2.155 0.881 0.994
All data are reported as mean ± standard deviation, n= 3 per experiment
Figure 2 . Drug release profile of all formulations from T-01 – T-04
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Figure 3. Graph of Korsmeyer-Peppas Model for formulation T-01
Figure 4. Graph of Korsmeyer-Peppas Model for formulation T-02
Figure 5. Graph of Korsmeyer-Peppas Model for formulation T-03
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DISCUSSION
Orally administered dosage forms are designed in such a 
way to release most of their drug in the segment of GIT 
from which maximum absorption of the incorporated 
drug takes place. On the other hand, salts of weakly acidic 
drugs are shown to have much higher dissolution profiles 
than from their free acidic forms. Diclofenac a phenylacetic 
acid derivative is available in the form of free acid as well as 
sodium and potassium salts. To date most of the marketed 
products of diclofenac are available as sodium or potassium 
salts as they show enhanced solubility profile than the free 
acid form. Typical dosage forms of diclofenac are available 
as delayed release (DR) or sustained release (SR) for the 
sodium salt and immediate release (IR) for the potassium 
salt claiming to have greater solubility in the stomach in 
situations when quick action is desired. The current work 
aimed to combine both technologies in a single dosage 
form by incorporating salts of diclofenac like potassium 
and sodium providing immediate and sustained release 
effect respectively. Diclofenac potassium is formulated as 
orodispersible layer to provide immediate release in the 
oral cavity while considering the susceptibility of diclofenac 
sodium to the gastric environment it is formulated as 
sustained release core to withstand the harsh environment 
of stomach. In recent years, an increased attention has 
been paid to formulating not only rapid disintegrating/
dissolving tablets but also to oral disintegrating tablets that 
are intended to disintegrate and dissolve in the mouth. 
Most of the studies focuses on the functional properties 
of these super-disintegrant and relating them to the 
disintegrating efficiency and release rate. The disruption of 
the tablet takes place either because of the swelling of these 
super-disintegrant or through capillary action increasing 
their volume by many folds. Sodium starch glycolate, the 
anionic sodium salt of carboxymethyl ether is used as 
super-disintegrant for orodispersible tablets (ODT) which 
is characterized by very short disintegration time. Its 
disintegrating efficiency depends on the source of starch 
from which it is synthesized (potato starch source with 
ideal disintegrating properties) as well as on the degree 
of crosslinking. The introduction of large hydrophilic 
carboxymethyl groups helps in disrupting the hydrogen 
bonding between the polymer allowing water to penetrate 
the molecule while the degree of crosslinking reduces 
the water-soluble portion of polymer and the viscosity of 
dispersion medium. The sodium starch glycolate used 
in current experiment exhibited ideal super-disintegrant 
properties allowing the tablet to disintegrate within a matter 
of seconds without the need of water. The concentration 
of super-disintegrant was found to have a significant 
effect on disintegration time which is evident from the 
result of formulation T-02 where the amount of Primogel® 
is decreased to 20mg/tab and the disintegration time is 
increased to 30 sec. while the reverse phenomenon was 
observed in formulation T-03. The gelling ability of HPMC 
in physiological salt fluids like simulated intestinal fluid 
affects the release of drug from the matrix. Moreover, from 
the in-vitro release data it was evident that hydroxypropyl 
methyl cellulose (HPMC K15) as release modifier could 
be a better choice to formulate sustained release tablets of 
diclofenac sodium. The results obtained for formulation 
T-04 are strictly according to USP which states that not 
less than 65% drug should be released after 10 h. The 
polymer drug ratio was found to be an important parameter 
in retarding drug release from the matrices. Direct 
Figure 6. Graph of Korsmeyer-Peppas Model for formulation T-04
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compression method was found to be an easy and efficient 
way of making fast disintegrating tablet while HPMC can 
be used successfully to formulate sustained release dosage 
form. Due to time constraint the current project could not 
be extended to the stability studies and in-vivo evaluation 
however these studies can be conducted in the future. This 
project will help patients in improving compliance because 
of the reduced dosing frequency, quick and prolonged onset 
of action and will open new avenues for researchers to 
extend this methodology to other drugs whose rapid action 
is required and are suitable for oral route.
CONCLUSION
The outer orodispersible layer of diclofenac potassium 
and sustained release inner core of diclofenac sodium in 
a single tablet was successfully formulated which was the 
primary objective of the research. The retarding effect on 
drug release was significantly associated with increasing 
the concentration of HPMC. The stability studies and In-
vivo evaluation of the tablets is thus recommended as future 
objective.
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Ağızda dağılan tabaka olarak diklofenak potasyum, 
geciktirilmiş salım çekirdeği olarak diklofenak sodyum 
içeren iki tabakalı tabletin formülasyonu ve değerlendirilmesi
ÖZ
Diklofenak, bir fenilasetik asit türevi olup uzun yıllardan beri 
antienfamatuvar ve analjezik bir ilaç olarak kullanılmaktadır 
ancak bu etken maddeden hareketle hemen salım için yükleme 
dozu içeren geciktirilmiş salım formülasyonunun hazırlanması 
istenmektedir. Bu çalışmanın amacı, ağızda dağılan tabaka 
olarak diklofenak potasyum, geciktirilmiş salım çekirdeği 
olarak diklofenak sodyum içeren iki tabakalı tabletlerin 
formülasyonu ve değerlendirilmesidir. Diklofenak sodyum 
içeren çekirdek yaş granülasyon yöntemi ile hazırlanırken 
ağızda dağılan dış tabaka direct basım yöntemiyle ve süper 
dağıtıcı olarak sodyum nişasta glikolat varlığında hazırlandı. 
Toz karışımı hem basım öncesi hem de basım sonrası özellikleri 
açısından değerlendirildi. Toz karışımının ve tabletlerin fiziksel 
özelliklerinin zorunlu standartlarla uyumlu olduğu görüldü. 
Ağızda dağılan kısmın 30 saniyeden kısa bir sürede dağılarak 
yükleme dozu olan diklofenak potasyumu saldığı, çekirdek 
kısmının ise simule bağırsak sıvısında (pH 6.8), 10 saate kadar 
diklofenak sodyum salınımı sağladığı tespit edildi. Kinetik ile 
ilgili veriler incelendiğinde, tabletin non-fickian salım gösterdiği 
ve Korsmeyer-Peppas modeline uygun olduğu tespit edildi. Tek 
bir tablet içeriğinde, ağızda dağılan tabaka olarak diklofenak 
potasyum, geciktirilmiş salım çekirdeği olarak diklofenak 
sodyum içeren ve süper dağıtıcı olarak sodyum nişasta glikolat 
içeren tabletlerin formülasyonu başarıyla yapıldı.
Anahtar Kelimeler: Ağızda dağılan tablet, geciktirilmiş salım, 
diklofenak, direkt basım, iki tabakalı tablet
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